Piramal Pharma Limited (PPLPHARMA) Share Price

NSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE0DK501011

₹213.18-0.02 (-0.01%)

Key metrics

Market Cap
₹28,249 Cr
P/E Ratio
EPS
-2.36
Book Value
61.41
P/B Ratio
3.5
ROE
-3.99%
ROCE
1.12%
Debt / Equity
0.7
Net Margin
-3.72%
Revenue Growth
-3.33%
Profit Growth
-457.66%
Dividend Yield
0.08%
52W High
₹220.36
52W Low
₹132.30
Market Cap Band
large cap
Face Value
10

Ratios computed from the annual results period ending 2026-03-31.

About Piramal Pharma Limited

Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing; offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain management drugs, and other generic and speciality products; and analgesics, skin care, vitamin and mineral supplement, kids' wellness, digestives, and women's health, as well as geriatric care. In addition, the company operates as a contract development and manufacturing organization, providing process development, scale-up, and GMP manufacturing services for vaccines and biologics. The company was incorporated in 2020 and is based in Mumbai, India.

Headquarters
Mumbai, India
Employees
7,120
Promoter Holding
54.53%

The full Piramal Pharma Limited analysis

Create a free account to open the complete PPLPHARMA deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.

  • 10-year financialsIncome statement, balance sheet and cash flow, year by year.
  • Valuation & fair valueFair-value estimates, quality scores and a value grade.
  • Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
  • Shareholding historyPromoter, FII, DII and public holdings across every quarter.
  • Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
  • Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.